GIFLF:OTCMKTS
Grifols SA Class A
11,13 US$
0,00%
(0,00) 1D
15 sht, 3:11:14 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për GIFLF...
Kapitalizimi i tregut
6,69 mld
Vëllimi mesatar
543,00
Vëllimi
0,00
Maksimumi 52-javor
12,90 US$
Minimumi 52-javor
10,13 US$
Beta
0,90
Aksionet në qarkullim
426,13 mln
Numri i punonjësve
25 mijë
Kapitalizimi i tregut
6,69 mld
Vëllimi mesatar
543,00
Vëllimi
0,00
Maksimumi 52-javor
12,90 US$
Minimumi 52-javor
10,13 US$
Beta
0,90
Aksionet në qarkullim
426,13 mln
Numri i punonjësve
25 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
ad-hoc-news.de
·
3 orë më parë
Grifols stock trades at EUR 10.03 with EUR 6.8 billion market value
AD HOC NEWS
·
2 ditë më parë
Grifols stock ends the week at EUR 9.88 within a EUR 9.73-9.97 range
AD HOC NEWS
·
2 ditë më parë
Grifols stock after-hours at EUR 9.88: plus 0.51 percent
AD HOC NEWS
·
3 ditë më parë
Grifols signed a 40 GWh PPA and Grifols stock gained 1.22 percent
Profili
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Rreth Grifols SA Class A
Drejtori ekzekutivNacho Abia
Punonjësit25 mijë
Themeluar më18 nën 1940
Selia-
Sektori-
Uebsajtigrifols.com